USANA Health Sciences (USNA) News Today

USANA Health Sciences, Inc. (NYSE: USNA) is under pressure after reporting weaker-than-expected third-quarter results and lowering its full-year outlook. Sales and adjusted EBITDA declined year over year, although the company’s net loss narrowed.

• Positive Sentiment: USANA’s BiOmega omega-3 supplement again earned ConsumerLab’s Seal of Approval, providing independent validation of its quality and purity. USANA BiOmega earns ConsumerLab Seal of Approval
• Neutral Sentiment: The quarterly net loss narrowed to $5.6 million from $6.5 million a year earlier; adjusted loss per share improved to $0.11 from $0.15. USANA reports third-quarter 2026 results
• Negative Sentiment: Net sales fell 4% year over year to $206 million, below the $217.4 million analyst consensus. Adjusted EBITDA also decreased to $12.1 million from $13.8 million. The adjusted loss of $0.11 per share missed expectations for $0.11 in earnings, a sharp disappointment despite the year-over-year improvement. USANA Q3 loss narrows, sales decline and outlook lowered
• Negative Sentiment: USANA lowered its FY2026 outlook, now expecting net sales to approach $900 million and adjusted EBITDA of approximately $77 million. The reduced forecast adds to concerns about the company’s declining sales and near-term earnings performance. USANA updates sales and adjusted EBITDA outlook